Loading clinical trials...
Loading clinical trials...
A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients With Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Conditions
Interventions
Cemiplimab-Rwlc
Locations
2
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
Moffitt Cancer Center
Tampa, Florida, United States
Start Date
June 25, 2020
Primary Completion Date
May 26, 2022
Completion Date
May 26, 2022
Last Updated
November 4, 2022
NCT05075980
NCT06659146
NCT05108090
NCT06008977
NCT06823479
NCT05025813
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions